|
1
|
Thanopoulou E and Judson I: The safety
profile of imatinib in CML and GIST: long-term considerations. Arch
Toxicol. 86:1–12. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Druker BJ and Lydon NB: Lessons learned
from the development of an abl tyrosine kinase inhibitor for
chronic myelogenous leukemia. J Clin Invest. 105:3–7. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Deininger MOBS, Guilhot F, Goldman JM,
Hochhaus A, Hughes TP, Radich JP, Hatfield AK, Mone M, Filian J,
Reynolds J, Gathmann I, Larson RA and Druker BJ: International
randomized study of interferon vs STI571 (IRIS) 8-year follow up:
sustained survival and low risk for progression or events in
patients with newly diagnosed chronic myeloid leukemia in chronic
phase (CML-CP) treated with imatinib. Blood (ASH Annual Meeting
Abstracts). 114:4622009.
|
|
4
|
Branford S, Rudzki Z, Walsh S, et al: High
frequency of point mutations clustered within the adenosine
triphosphate-binding region of BCR/ABL in patients with chronic
myeloid leukemia or Ph-positive acute lymphoblastic leukemia who
develop imatinib (STI571) resistance. Blood. 99:3472–3475. 2002.
View Article : Google Scholar
|
|
5
|
Eechoute K, Sparreboom A, Burger H, et al:
Drug transporters and imatinib treatment: implications for clinical
practice. Clin Cancer Res. 17:406–415. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hegedus T, Orfi L, Seprodi A, Váradi A,
Sarkadi B and Kéri G: Interaction of tyrosine kinase inhibitors
with the human multidrug transporter proteins, MDR1 and MRP1.
Biochim Biophys Acta. 1587:318–325. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hamada A, Miyano H, Watanabe H and Saito
H: Interaction of imatinib mesilate with human P-glycoprotein. J
Pharmacol Exp Ther. 307:824–828. 2003. View Article : Google Scholar
|
|
8
|
Thomas J, Wang L, Clark RE and Pirmohamed
M: Active transport of imatinib into and out of cells: implications
for drug resistance. Blood. 104:3739–3745. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Callen DF, Baker E, Simmers RN, Seshadri R
and Roninson IB: Localization of the human multiple-drug resistance
gene, MDR1, to 7q21.1. Human Genet. 77:142–144. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bodor M, Kelly EJ and Ho RJ:
Characterization of the human MDR1 gene. AAPS J. 7:E1–E5. 2005.
View Article : Google Scholar
|
|
11
|
Fletcher JI, Haber M, Henderson MJ and
Norris MD: ABC transporters in cancer: more than just drug efflux
pumps. Nat Rev Cancer. 10:147–156. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fung KL and Gottesman MM: A synonymous
polymorphism in a common MDR1 (ABCB1) haplotype shapes protein
function. Biochim Biophys Acta. 1794:860–871. 2009. View Article : Google Scholar
|
|
13
|
Kimchi-Sarfaty C, Marple AH, Shinar S, et
al: Ethnicity-related polymorphisms and haplotypes in the human
ABCB1 gene. Pharmacogenomics. 8:29–39. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kimchi-Sarfaty C, Oh JM, Kim IW, et al: A
‘silent’ polymorphism in the MDR1 gene changes substrate
specificity. Science. 315:525–528. 2007.
|
|
15
|
Vivona D, Bueno CT, Lima LT, et al: ABCB1
haplotype is associated with major molecular response in chronic
myeloid leukemia patients treated with standard-dose of imatinib.
Blood Cells Mol Dis. 48:132–136. 2012. View Article : Google Scholar
|
|
16
|
Rodrigues AC, Rebecchi IM, Bertolami MC,
Faludi AA, Hirata MH and Hirata RD: High baseline serum total and
LDL cholesterol levels are associated with MDR1 haplotypes in
Brazilian hypercholesterolemic individuals of European descent.
Braz J Med Biol Res. 38:1389–1397. 2005. View Article : Google Scholar
|
|
17
|
Cascorbi I, Gerloff T, Johne A, et al:
Frequency of single nucleotide polymorphisms in the P-glycoprotein
drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther.
69:169–174. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Branford S and Hughes T: Diagnosis and
monitoring of chronic myeloid leukemia by qualitative and
quantitative RT-PCR. Methods Mol Med. 125:69–92. 2006.PubMed/NCBI
|
|
19
|
Vandesompele J, De Preter K, Pattyn F, et
al: Accurate normalization of real-time quantitative RT-PCR data by
geometric averaging of multiple internal control genes. Genome
Biol. 3:RESEARCH00342002. View Article : Google Scholar
|
|
20
|
Albermann N, Schmitz-Winnenthal FH,
Z’graggen K, et al: Expression of the drug transporters MDR1/ABCB1,
MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood
mononuclear cells and their relationship with the expression in
intestine and liver. Biochem Pharmacol. 70:949–958. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rodrigues AC, Curi R, Britto LR, et al:
Down-regulation of ABCB1 transporter by atorvastatin in a human
hepatoma cell line and in human peripheral blood mononuclear cells.
Biochim Biophys Acta. 1760:1866–1873. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Larson RA, Druker BJ, Guilhot F, et al:
Imatinib pharmacokinetics and its correlation with response and
safety in chronic-phase chronic myeloid leukemia: a subanalysis of
the IRIS study. Blood. 111:4022–4028. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ajimura TO, Borges KB, Ferreira AF, de
Castro FA and de Gaitani CM: Capillary electrophoresis method for
plasmatic determination of imatinib mesylate in chronic myeloid
leukemia patients. Electrophoresis. 32:1885–1892. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jamroziak K, Młynarski W, Balcerczak E, et
al: Functional C3435T polymorphism of MDR1 gene: an impact on
genetic susceptibility and clinical outcome of childhood acute
lymphoblastic leukemia. Eur J Haematol. 72:314–321. 2004.
View Article : Google Scholar
|
|
25
|
Shitara K, Matsuo K, Ito S, et al: Effects
of genetic polymorphisms in the ABCB1 gene on clinical outcomes in
patients with gastric cancer treated by second-line chemotherapy.
Asian Pac J Cancer Prev. 11:447–452. 2010.
|
|
26
|
Deenen MJ, Cats A, Beijnen JH and
Schellens JH: Part 2: pharmacogenetic variability in drug transport
and phase I anticancer drug metabolism. Oncologist. 16:820–834.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dulucq S, Bouchet S, Turcq B, et al:
Multidrug resistance gene (MDR1) polymorphisms are associated with
major molecular responses to standard-dose imatinib in chronic
myeloid leukemia. Blood. 112:2024–2027. 2008. View Article : Google Scholar
|
|
28
|
Hung CC, Tai JJ, Lin CJ, Lee MJ and Liou
HH: Complex haplotypic effects of the ABCB1 gene on epilepsy
treatment response. Pharmacogenomics. 6:411–417. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wong M, Evans S, Rivory LP, et al: Hepatic
technetium Tc 99m-labeled sestamibi elimination rate and ABCB1
(MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in
patients with cancer. Clin Pharmacol Ther. 77:33–42. 2005.
View Article : Google Scholar
|
|
30
|
Aarnoudse AJ, Dieleman JP, Visser LE, et
al: Common ATP-binding cassette B1 variants are associated with
increased digoxin serum concentration. Pharmacogenet Genomics.
18:299–305. 2008. View Article : Google Scholar
|
|
31
|
Keskitalo JE, Kurkinen KJ, Neuvoneni PJ
and Niemi M: ABCB1 haplotypes differentially affect the
pharmacokinetics of the acid and lactone forms of simvastatin and
atorvastatin. Clin Pharmacol Ther. 84:457–461. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xu P, Jiang ZP, Zhang BK, Tu JY and Li HD:
Impact of MDR1 haplotypes derived from C1236T, G2677T/A and C3435T
on the pharmacokinetics of single-dose oral digoxin in healthy
Chinese volunteers. Pharmacology. 82:221–227. 2008. View Article : Google Scholar
|
|
33
|
Wu H, Kang H, Liu Y, et al: Roles of ABCB1
gene polymorphisms and haplotype in susceptibility to breast
carcinoma risk and clinical outcomes. J Cancer Res Clin Oncol.
138:1449–1462. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim RB, Leake BF, Choo EF, et al:
Identification of functionally variant MDR1 alleles among European
Americans and African Americans. Clin Pharmacol Ther. 70:189–199.
2001. View Article : Google Scholar
|
|
35
|
Tapaninen T, Neuvonen PJ and Niemi M:
Effect of ABCB1 haplotypes on the pharmacokinetics and
renin-inhibiting effect of aliskiren. Eur J Clin Pharmacol.
66:865–870. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jensen BP, Roberts RL, Vyas R, Bonke G,
Jardine DL and Begg EJ: Influence of ABCB1 (P-glycoprotein)
haplotypes on nortriptyline pharmacokinetics and
nortriptyline-induced postural hypotension in healthy volunteers.
Br J Clin Pharmacol. 73:619–628. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Marsh S, Paul J, King CR, Gifford G,
McLeod HL and Brown R: Pharmacogenetic assessment of toxicity and
outcome after platinum plus taxane chemotherapy in ovarian cancer:
the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol.
25:4528–4535. 2007. View Article : Google Scholar
|
|
38
|
Picard S, Titier K, Etienne G, et al:
Trough imatinib plasma levels are associated with both cytogenetic
and molecular responses to standard-dose imatinib in chronic
myeloid leukemia. Blood. 109:3496–3499. 2007. View Article : Google Scholar
|
|
39
|
Marin D, Bazeos A, Mahon FX, et al:
Adherence is the critical factor for achieving molecular responses
in patients with chronic myeloid leukemia who achieve complete
cytogenetic responses on imatinib. J Clin Oncol. 28:2381–2388.
2010. View Article : Google Scholar
|
|
40
|
Takahashi N, Wakita H, Miura M, et al:
Correlation between imatinib pharmacokinetics and clinical response
in Japanese patients with chronic-phase chronic myeloid leukemia.
Clin Pharmacol Ther. 88:809–813. 2010. View Article : Google Scholar
|
|
41
|
Yamakawa Y, Hamada A, Nakashima R, et al:
Association of genetic polymorphisms in the influx transporter
SLCO1B3 and the efflux transporter ABCB1 with imatinib
pharmacokinetics in patients with chronic myeloid leukemia. Ther
Drug Monit. 33:244–250. 2011.PubMed/NCBI
|
|
42
|
Gurney H, Wong M, Balleine RL, et al:
Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype.
Clin Pharmacol Ther. 82:33–40. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dey S: Single nucleotide polymorphisms in
human P-glycoprotein: its impact on drug delivery and disposition.
Expert Opin Drug Deliv. 3:23–35. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rautio J, Humphreys JE, Webster LO, et al:
In vitro p-glycoprotein inhibition assays for assessment of
clinical drug interaction potential of new drug candidates: a
recommendation for probe substrates. Drug Metab Dispos. 34:786–792.
2006. View Article : Google Scholar
|
|
45
|
Hoffmeyer S, Burk O, von Richter O, et al:
Functional polymorphisms of the human multidrug-resistance gene:
multiple sequence variations and correlation of one allele with
P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci
USA. 97:3473–3478. 2000. View Article : Google Scholar
|
|
46
|
Tsai CJ, Sauna ZE, Kimchi-Sarfaty C,
Ambudkar SV, Gottesman MM and Nussinov R: Synonymous mutations and
ribosome stalling can lead to altered folding pathways and distinct
minima. J Mol Biol. 383:281–291. 2008. View Article : Google Scholar : PubMed/NCBI
|
